302 related articles for article (PubMed ID: 11522017)
1. Plasma PAI-1 levels in obese children--effect of weight loss and influence of PAI-1 promoter 4G/5G genotype.
Estellés A; Dalmau J; Falcó C; Berbel O; Castelló R; España F; Aznar J
Thromb Haemost; 2001 Aug; 86(2):647-52. PubMed ID: 11522017
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor-1 levels in severe and morbid obesity. Effect of weight loss and influence of 4G/5G polymorphism.
Solá E; Vayá A; España F; Castelló R; Ramón LA; Hernández-Mijares A; Vicente V; Estellés A
Thromb Res; 2008; 122(3):320-7. PubMed ID: 18037477
[TBL] [Abstract][Full Text] [Related]
3. The effect of plasminogen activator inhibitor-1 gene 4G/5G polymorphism on glucose and lipid metabolisms in Turkish obese children.
Kinik ST; Ataç FB; Verdi H; Cetintaş S; Sahin FI; Ozbek N
Clin Endocrinol (Oxf); 2005 May; 62(5):607-10. PubMed ID: 15853833
[TBL] [Abstract][Full Text] [Related]
4. Role of the 4G/5G polymorphism of PaI-1 gene promoter on PaI-1 levels in obese patients: influence of fat distribution and insulin-resistance.
Sartori MT; Vettor R; De Pergola G; De Mitrio V; Saggiorato G; Della Mea P; Patrassi GM; Lombardi AM; Fabris R; Girolami A
Thromb Haemost; 2001 Nov; 86(5):1161-9. PubMed ID: 11816701
[TBL] [Abstract][Full Text] [Related]
5. PAI-1 gene 4G/5G polymorphism, cytokine levels and their relations with metabolic parameters in obese children.
Kinik ST; Ozbek N; Yuce M; Yazici AC; Verdi H; Ataç FB
Thromb Haemost; 2008 Feb; 99(2):352-6. PubMed ID: 18278185
[TBL] [Abstract][Full Text] [Related]
6. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism.
Stegnar M; Uhrin P; Peternel P; Mavri A; Salobir-Pajnic B; Stare J; Binder BR
Thromb Haemost; 1998 May; 79(5):975-9. PubMed ID: 9609232
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease.
Grancha S; Estellés A; Tormo G; Falco C; Gilabert J; España F; Cano A; Segui R; Aznar J
Thromb Haemost; 1999 Apr; 81(4):516-21. PubMed ID: 10235431
[TBL] [Abstract][Full Text] [Related]
8. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis.
Sartori MT; Wiman B; Vettore S; Dazzi F; Girolami A; Patrassi GM
Thromb Haemost; 1998 Dec; 80(6):956-60. PubMed ID: 9869167
[TBL] [Abstract][Full Text] [Related]
9. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels.
Matsubara Y; Murata M; Isshiki I; Watanabe R; Zama T; Watanabe G; Watanabe K; Ikeda Y
Int J Hematol; 1999 Jan; 69(1):43-7. PubMed ID: 10641442
[TBL] [Abstract][Full Text] [Related]
10. The -675 4G/5G polymorphism at the Plasminogen Activator Inhibitor 1 (PAI-1) gene modulates plasma Plasminogen Activator Inhibitor 1 concentrations in response to dietary fat consumption.
Pérez-Martínez P; Adarraga-Cansino MD; Fernández de la Puebla RA; Blanco-Molina A; Delgado-Lista J; Marín C; Ordovás JM; López-Miranda J; Pérez-Jiménez F
Br J Nutr; 2008 Apr; 99(4):699-702. PubMed ID: 17903340
[TBL] [Abstract][Full Text] [Related]
11. PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample.
Meigs JB; Dupuis J; Liu C; O'Donnell CJ; Fox CS; Kathiresan S; Gabriel SB; Larson MG; Yang Q; Herbert AG; Wilson PW; Feng D; Tofler GH; Cupples LA
Obesity (Silver Spring); 2006 May; 14(5):753-8. PubMed ID: 16855181
[TBL] [Abstract][Full Text] [Related]
12. Effect of 4G/5G PAI-1 polymorphism on the response of PAI-1 activity to vitamin E supplementation in Type 2 diabetic patients.
Testa R; Bonfigli AR; Sirolla C; Boemi M; Manfrini S; Mari D; Testa I; Sacchi E; Franceschi C
Diabetes Nutr Metab; 2004 Aug; 17(4):217-21. PubMed ID: 15575342
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and endometriosis. Influence of PAI-1 polymorphism on PAI-1 antigen and mRNA expression.
Ramón LA; Gilabert-Estellés J; Cosín R; Gilabert J; España F; Castelló R; Chirivella M; Romeu A; Estellés A
Thromb Res; 2008; 122(6):854-60. PubMed ID: 18423526
[TBL] [Abstract][Full Text] [Related]
14. Regular exercise, plasminogen activator inhibitor-1 (PAI-1) activity and the 4G/5G promoter polymorphism in the PAI-1 gene.
Väisänen SB; Humphries SE; Luong LA; Penttilä I; Bouchard C; Rauramaa R
Thromb Haemost; 1999 Sep; 82(3):1117-20. PubMed ID: 10494774
[TBL] [Abstract][Full Text] [Related]
15. Relationship between gene polymorphism of the PAI-1 promoter and myocardial infarction.
Fu L; Jin H; Song K; Zhang C; Shen J; Huang Y
Chin Med J (Engl); 2001 Mar; 114(3):266-9. PubMed ID: 11780311
[TBL] [Abstract][Full Text] [Related]
16. The common -675 4G/5G polymorphism in the plasminogen activator inhibitor -1 gene is strongly associated with obesity.
Hoffstedt J; Andersson IL; Persson L; Isaksson B; Arner P
Diabetologia; 2002 Apr; 45(4):584-7. PubMed ID: 12032637
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.
Castelló R; España F; Vázquez C; Fuster C; Almenar SM; Aznar J; Estellés A
Thromb Res; 2006; 117(5):487-92. PubMed ID: 15907980
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.
Eroglu A; Ulu A; Cam R; Akar N
J BUON; 2006; 11(4):481-4. PubMed ID: 17309181
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
Jorgenson E; Deitcher SR; Cicek M; Liu X; Plummer S; Casey G; Witte JS
Prostate; 2007 Feb; 67(2):172-7. PubMed ID: 17044080
[TBL] [Abstract][Full Text] [Related]
20. [The influence of I/D polymorphism of the angiotensin I converting enzyme (ACE) gene and 4G/5G polymorphism of plasminogen activator inhibitor (PAI-1) gene promoter on the haemostatic system in patients with essential hypertension and dyslipidemia].
Nowakowska A
Ann Acad Med Stetin; 2005; 51(1):95-105. PubMed ID: 16496609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]